Valerie Reyna was on the National Academies of Sciences, Engineering and Medicine Committee that produced the report, Pain Management and the Opioid Epidemic. Here are links to media coverage of the report.
In a sweeping report Thursday, the National Academies of Sciences, Engineering and Medicine pushed the FDA to bolster a public health approach that already has resulted in one painkiller being pulled from the market. Last week, the maker of opioid painkiller Opana ER withdrew its drug at the FDA’s request following a 2015 outbreak of HIV and hepatitis C in southern Indiana linked to sharing needles to inject the pills.
Los Angeles Times
In a comprehensive report on what must be done to staunch the toll of opiates in the United States, a report released by the National Academies of Science, Engineering and Medicine makes clear that steps taken to prevent the creation of future opiate addicts will drive some now dependent on these drugs toward street drugs such as fentanyl and heroin.
To help bolster its campaign against an epidemic of opioid abuse that now kills about 90 people a day, the U.S. Food and Drug Administration (FDA) last year called for help from an independent advisory panel. The resulting report, released today by the National Academies of Sciences, Engineering, and Medicine, makes some strong prescriptions. Among its assorted recommendations—from supporting state syringe exchange programs to increasing federal funding for neurobiology research—the panel suggests that FDA dramatically expand the types of evidence it requires from companies to show that an opioid is safe and effective, both before and after it gets market approval.
When the U.S. Food and Drug Administration screens new opioid drugs it should better anticipate how people might abuse them in the real world, the National Academies of Sciences, Engineering and Medicine warns in a major report issued Thursday on the country’s opioid crisis, which kills 91 people a day—often via overdoses on prescription drugs. The FDA needs to move beyond its traditional focus on clinical studies about drug effectiveness and side effects, and to seek public health data on potential abuse, the Academies advises in its 400-page proposal for targeting the deadly issue.
However, experts say there's no quick fix for the opioid epidemic. According to a new report from the U.S. National Academies of Sciences, Engineering and Medicine, it will take years of coordinated effort on the part of local, state and federal agencies to halt and reverse the drug crisis.
In March 2016, the FDA asked the National Academies of Sciences, Engineering, and Medicine (NASEM) to outline the state of the science regarding prescription opioid abuse and misuse, as well as the evolving role that opioids play in pain management. We greatly appreciate all the work done by NASEM over the past year to produce the comprehensive report released today, which includes recommendations for the FDA and others on this important issue.